ImmunityBio, Inc. (NASDAQ:IBRX) gapped up before the market opened on Friday . The stock had previously closed at $9.74, but opened at $10.14. ImmunityBio shares last traded at $9.76, with a volume of 391 shares changing hands.
Separately, Zacks Investment Research downgraded ImmunityBio from a “hold” rating to a “sell” rating in a report on Wednesday.
The firm’s fifty day simple moving average is $10.89.
In other ImmunityBio news, Director Cheryl Cohen sold 9,976 shares of ImmunityBio stock in a transaction dated Friday, August 20th. The stock was sold at an average price of $10.00, for a total transaction of $99,760.00. Following the transaction, the director now directly owns 215,418 shares of the company’s stock, valued at approximately $2,154,180. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 68,175 shares of company stock worth $688,734 over the last ninety days. Company insiders own 82.80% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in IBRX. US Bancorp DE acquired a new position in ImmunityBio during the 1st quarter worth about $95,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of ImmunityBio in the 1st quarter worth about $196,000. The Manufacturers Life Insurance Company bought a new position in shares of ImmunityBio in the 1st quarter worth about $455,000. Victory Capital Management Inc. bought a new position in shares of ImmunityBio in the 1st quarter worth about $846,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new position in shares of ImmunityBio in the 1st quarter worth about $1,043,000. 25.41% of the stock is currently owned by hedge funds and other institutional investors.
About ImmunityBio (NASDAQ:IBRX)
ImmunityBio, Inc is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory.
Featured Story: Growth Stocks
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.